EA201800564A1 - Штамм akkermansia glycaniphilus, композиция, содержащая штамм, применение штамма и композиции, способ повышения уровня штамма akkermansia glycaniphilus в желудочно-кишечном тракте - Google Patents

Штамм akkermansia glycaniphilus, композиция, содержащая штамм, применение штамма и композиции, способ повышения уровня штамма akkermansia glycaniphilus в желудочно-кишечном тракте

Info

Publication number
EA201800564A1
EA201800564A1 EA201800564A EA201800564A EA201800564A1 EA 201800564 A1 EA201800564 A1 EA 201800564A1 EA 201800564 A EA201800564 A EA 201800564A EA 201800564 A EA201800564 A EA 201800564A EA 201800564 A1 EA201800564 A1 EA 201800564A1
Authority
EA
Eurasian Patent Office
Prior art keywords
strain
akkermansia
composition
glycaniphilus
akkermansia glycaniphilus
Prior art date
Application number
EA201800564A
Other languages
English (en)
Inventor
Виллем Мейндерт ДЕ ВОС
Клара Белзер
Original Assignee
Вагенинген Университет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вагенинген Университет filed Critical Вагенинген Университет
Publication of EA201800564A1 publication Critical patent/EA201800564A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Из свежих фекалий сетчатого питона выделен новый вид рода Akkermansia. Этот вид назван Akkermansia glycaniphilus. Он способен расти, используя слизь в качестве единственного источника углерода и азота. Вид может быть использован в качестве лекарства, пробиотика или косметического средства, например, для содействия снижению массы тела, для стимуляции иммунной системы кишечника, для поддержания, восстановления и/или повышения физической целостности мукозального барьера кишечника и для профилактики или лечения разнообразных ассоциированных заболеваний или нарушений.
EA201800564A 2016-04-11 2017-04-11 Штамм akkermansia glycaniphilus, композиция, содержащая штамм, применение штамма и композиции, способ повышения уровня штамма akkermansia glycaniphilus в желудочно-кишечном тракте EA201800564A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16164743 2016-04-11
PCT/EP2017/058700 WO2017178496A1 (en) 2016-04-11 2017-04-11 Novel bacterial species

Publications (1)

Publication Number Publication Date
EA201800564A1 true EA201800564A1 (ru) 2019-06-28

Family

ID=55755363

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201800564A EA201800564A1 (ru) 2016-04-11 2017-04-11 Штамм akkermansia glycaniphilus, композиция, содержащая штамм, применение штамма и композиции, способ повышения уровня штамма akkermansia glycaniphilus в желудочно-кишечном тракте

Country Status (17)

Country Link
US (1) US11202807B2 (ru)
EP (1) EP3443071B1 (ru)
JP (1) JP7012377B2 (ru)
KR (1) KR20180133443A (ru)
CN (1) CN109415683B (ru)
AU (1) AU2017251253B2 (ru)
BR (1) BR112018070962A2 (ru)
CA (1) CA3020454A1 (ru)
DK (1) DK3443071T3 (ru)
EA (1) EA201800564A1 (ru)
ES (1) ES2905784T3 (ru)
IL (1) IL262258B (ru)
MX (1) MX2018012408A (ru)
NZ (1) NZ747179A (ru)
PL (1) PL3443071T3 (ru)
PT (1) PT3443071T (ru)
WO (1) WO2017178496A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115919906A (zh) 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
NZ747179A (en) * 2016-04-11 2024-07-05 Univ Wageningen Novel bacterial species
JP7464931B2 (ja) * 2018-04-05 2024-04-10 丸共バイオフーズ株式会社 新規ムチン型糖タンパク質およびその用途
CN113038957A (zh) 2018-04-10 2021-06-25 谢尔塔治疗公司 微生物群
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
CN114786690A (zh) 2019-10-07 2022-07-22 谢尔塔治疗公司 治疗性药物组合物
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
CN111304133B (zh) * 2020-03-20 2023-01-13 苏州普瑞森生物科技有限公司 一种培养嗜黏蛋白阿克曼氏菌的培养基及其使用方法和应用
BE1029502B1 (fr) 2021-08-19 2023-01-17 The Akkermansia Company Composition comprenant de l'Akkermansia muciniphila pasteurisée pour le traitement ou la prévention de l'anxiété liée au syndrome du côlon irritable
BE1029496B1 (fr) 2021-08-19 2023-01-16 The Akkermansia Company Composition comprenant de l'Akkermansia muciniphila pasteurisée pour le traitement ou la prévention des troubles de la contractilité intestinale, en particulier des troubles de l'amplitude de la contractilité duodénale
KR102643788B1 (ko) * 2021-12-08 2024-03-07 (주)헬스바이옴 아커만시아속 미생물의 고수율 생산용 배지 조성물, 그를 이용한 배양방법 및 동결건조 방법
TW202346570A (zh) * 2022-05-20 2023-12-01 日商大塚製藥股份有限公司 屬於艾克曼氏菌(Akkermansia)屬之微生物
CN115252651B (zh) * 2022-06-08 2024-06-07 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌在制备防治高血压的组合物中的应用和含有其的组合物
FR3138770A1 (fr) * 2022-08-10 2024-02-16 Actina Ensemble de parties destine a moduler le microbiote intestinale, reduire la prise de poids et le stockage des graisses dans le foie
CN117796528B (zh) * 2023-12-29 2024-12-31 广西爱生生命科技有限公司 广西阿克曼氏菌菌株或其益生菌剂在制备延长寿命、抗衰老、延缓帕金森病的产品中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2753187T3 (en) 2011-08-30 2019-01-28 Caelus Pharmaceuticals B V Method of preventing and / or treating insulin resistance
CN104540962B (zh) * 2012-08-01 2017-09-19 深圳华大基因研究院 糖尿病生物标志物及其应用
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
US20140242654A1 (en) 2013-02-26 2014-08-28 Coskata, Inc. Butyrate Producing Clostridium species, Clostridium pharus
WO2014150094A1 (en) 2013-03-15 2014-09-25 University Of Florida Research Foundation, Inc. Butyrogenic bacteria as probiotics to treat clostridium difficile
AU2016258976B2 (en) * 2015-05-06 2021-02-25 Wageningen Universiteit Method of culturing Akkermansia
EP3347030B1 (en) * 2015-09-10 2021-07-14 Université catholique de Louvain Use of pasteurized akkermansia for treating metabolic disorders
EP3359171B1 (en) * 2015-10-05 2023-07-05 Schweizerisches Forschungsinstitut für Hochgebirgsklima und Medizin in Davos Use of akkermansia muciniphila for treating inflammatory conditions
WO2017146580A1 (en) * 2016-02-25 2017-08-31 Caelus Pharmaceuticals B.V. Compositions and methods for preventing and/or treating vitamin b12 deficiency
NZ747179A (en) * 2016-04-11 2024-07-05 Univ Wageningen Novel bacterial species
CN110551658A (zh) * 2019-09-12 2019-12-10 君维安(武汉)生命科技有限公司 一种嗜黏蛋白阿克曼氏菌的低氧培养方法

Also Published As

Publication number Publication date
NZ747179A (en) 2024-07-05
JP2019510520A (ja) 2019-04-18
PL3443071T3 (pl) 2022-03-28
PT3443071T (pt) 2022-01-19
AU2017251253B2 (en) 2023-01-05
EP3443071A1 (en) 2019-02-20
MX2018012408A (es) 2019-06-17
IL262258B (en) 2021-03-25
BR112018070962A2 (pt) 2019-01-29
US20190183941A1 (en) 2019-06-20
US11202807B2 (en) 2021-12-21
JP7012377B2 (ja) 2022-02-14
EP3443071B1 (en) 2022-01-05
KR20180133443A (ko) 2018-12-14
DK3443071T3 (da) 2022-01-31
WO2017178496A1 (en) 2017-10-19
IL262258A (en) 2018-11-29
CN109415683B (zh) 2022-04-15
CA3020454A1 (en) 2017-10-19
ES2905784T3 (es) 2022-04-12
AU2017251253A1 (en) 2018-11-01
CN109415683A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
EA201800564A1 (ru) Штамм akkermansia glycaniphilus, композиция, содержащая штамм, применение штамма и композиции, способ повышения уровня штамма akkermansia glycaniphilus в желудочно-кишечном тракте
EA201791518A1 (ru) Способы лечения заболеваний сетчатки
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
EA202091709A1 (ru) Ингибиторы днк-пк
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
MX2017004983A (es) Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
EA202091708A1 (ru) Ингибиторы днк-пк
PH12017501095A1 (en) Piperidine derivatives as hdac1/2 inhibitors
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
CN107405369A8 (zh) 包含细菌的组合物及将其用于治疗和/或预防胃肠道疾病、代谢疾病和/或其它疾病的方法
WO2017139697A8 (en) Bacteria engineered to treat diseases associated with hyperammonemia
PH12018501443A1 (en) Methods of administering hepcidin
BR112017017599A2 (pt) métodos para modular respostas imunológicas e inflamatórias pela administração de uma biomassa algal
MX2018015110A (es) Arn modificado que codifica polipeptidos de vegf-a. formulaciones y usos relacionados con los mismos.
MX2022004373A (es) Celulas madre modificadas y metodos de uso de las mismas.
EA202191115A1 (ru) Новые пиридазины
PH12017500743A1 (en) Tau protein production accelerator, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by tau protein deficiency
EA201792603A1 (ru) Ангиогенез с использованием стимулированных плацентарных стволовых клеток
PH12019501358A1 (en) Methods of administering hepcidin
MX2019006886A (es) Métodos para tratar enfermedades asociadas con células linfoides innatas del grupo 2 (ilc2).
MX2022004836A (es) Vacunas mejoradas para la papilomatosis respiratoria recurrente y métodos para su uso.